Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Financial Officer | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,166 |
Ending reported balance
After 2026-08-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-04 · Sale · Disposed 1,794 · Balance 43,133 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-08-04 · Sale · Disposed 2,967 · Balance 40,166 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2025 Filed May 2, 2025 22:18 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 6,198 | $11.33 | $70,242.55 |
DisclosureSEC source: 0001549595-25-000063 · wk-form4_1746224320.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,724 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.195 and the highest price at which shares were sold was $11.55. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · derivative · entry 7 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · derivative · entry 6 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · derivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,659 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,438 | $11.50 | $28,041.14 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · nonDerivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,922 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.05 and the highest price at which shares were sold was $11.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000059 · wk-form4_1746056112.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 22:29 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 700 | $15.13 | $10,590.79 |
DisclosureSEC source: 0001549595-25-000037 · wk-form4_1741040958.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,724 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $14.87 and the highest price at which shares were sold was $15.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 22:29 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,125 | $14.40 | $73,796.93 |
DisclosureSEC source: 0001549595-25-000037 · wk-form4_1741040958.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,424 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $13.87 and the highest price at which shares were sold was $14.84. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:12 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 34,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000034 · wk-form4_1739481136.xml · derivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,300 Underlying: Common Stock · 34,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:12 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.12 | $0.00 |
DisclosureSEC source: 0001549595-25-000034 · wk-form4_1739481136.xml · derivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-02-10 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 11, 2025, until the option is fully vested on February 10, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · derivative · entry 8 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · derivative · entry 7 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · derivative · entry 6 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,545 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 254 | $20.33 | $5,162.70 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · nonDerivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,549 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,557 | $19.81 | $50,645.99 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · nonDerivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,803 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000020 · wk-form4_1738284183.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 21:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,546 | $24.28 | $86,083.41 |
DisclosureSEC source: 0001549595-24-000153 · wk-form4_1730498227.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,724 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $24.04 and the highest price at which shares were sold was $24.70. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · derivative · entry 7 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · derivative · entry 6 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · derivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,431 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,368 | $24.31 | $57,554.24 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · nonDerivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,270 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000148 · wk-form4_1730334620.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 21:41 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 20,000 | $25.22 | $504,370.00 |
DisclosureSEC source: 0001549595-24-000112 · wk-form4_1724708492.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,002 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.00 and the highest price at which shares were sold was $25.58. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 100 | $22.22 | $2,222.00 |
DisclosureSEC source: 0001549595-24-000110 · wk-form4_1722553573.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,002 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,377 | $21.43 | $72,353.91 |
DisclosureSEC source: 0001549595-24-000110 · wk-form4_1722553573.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,102 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.08 and the highest price at which shares were sold was $22.05. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · derivative · entry 7 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · derivative · entry 6 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · derivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,317 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,490 | $20.67 | $51,462.57 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · nonDerivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,479 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000104 · wk-form4_1722380754.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 20:58 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 20,000 | $20.01 | $400,216.00 |
DisclosureSEC source: 0001549595-24-000088 · wk-form4_1718917093.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,333 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.00 and the highest price at which shares were sold was $20.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 02, 2024 Filed May 2, 2024 22:01 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,499 | $12.83 | $44,878.17 |
DisclosureSEC source: 0001549595-24-000057 · wk-form4_1714687275.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,333 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.65 and the highest price at which shares were sold was $13.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000055 · wk-form4_1714516403.xml · derivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000055 · wk-form4_1714516403.xml · derivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,203 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,387 | $12.04 | $16,702.53 |
DisclosureSEC source: 0001549595-24-000055 · wk-form4_1714516403.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,832 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.9050 and the highest price at which shares were sold was $12.2000. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000055 · wk-form4_1714516403.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000055 · wk-form4_1714516403.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 00:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 6,812 | $10.02 | $68,222.86 |
DisclosureSEC source: 0001549595-24-000034 · wk-form4_1708129211.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,333 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $10.00 and the highest price at which shares were sold was $10.17. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 12:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000020 · wk-form4_1707999800.xml · derivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 12:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001549595-24-000020 · wk-form4_1707999800.xml · derivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000009 · wk-form4_1706658780.xml · derivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,886 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000009 · wk-form4_1706658780.xml · derivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,089 Underlying: Common Stock · 2,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.